Biohaven autoimmune degraders clear key biomaker milestones as Phase 3 nears

Biohaven (NYSE:BHVN) reported positive preliminary clinical data from its ongoing Phase 1b trials evaluating two novel extracellular protein degraders, hitting key biological markers and clearing a path toward advanced clinical development.

The experimental therapies, targeting Graves' disease and IgA nephropathy, achieved rapid reductions in disease-driving antibodies while maintaining a highly favorable safety profile.

The clinical-stage biopharmaceutical company presented the patient data during its R&D and Analyst Day, showcasing the therapeutic potential of its proprietary MoDE and TRAP degrader platforms.

Both programs are slated to advance into pivotal Phase 3 clinical trials by mid-2026, which will utilize patient-friendly autoinjector devices for administration.

In patients with Graves' disease—an autoimmune disorder causing overactive thyroid function—Biohaven’s candidate BHV-1300 achieved deep and sustained reductions in pathogenic TSHR-IgG1 antibodies.

The treatment cut mean antibody levels by more than 80% over the 12-week study period.

Crucially, participants with overt hyperthyroidism saw their thyroid hormones normalize within weeks of beginning therapy, with median free T4 normalization occurring at three weeks and free T3 at five weeks.

Meanwhile, the company’s second candidate, BHV-1400, targeted galactose-deficient IgA1, the pathogenic antibody driver behind IgA nephropathy, a progressive kidney disease.

The TRAP degrader reduced these specific antibodies by more than 60% within 48 hours and by 70% within the first month of dosing.

This rapid antibody clearance correlated with early clinical improvements in patients, including favorable changes in estimated glomerular filtration rate (eGFR), spot urine protein-creatinine ratio (UPCR), and a notable reduction in hematuria.

Safety data across both studies remained highly encouraging to investors and clinicians alike.

Both BHV-1300 and BHV-1400 demonstrated pristine tolerability profiles, characterized entirely by mild, self-resolving adverse events.

No serious or severe adverse events were reported, and neither trial recorded any drug discontinuions or clinically significant laboratory abnormalities regarding liver enzymes or cholesterol levels.